Selenium and Antioxidative Capacity in Blood and Tissue of Cancer Patients Versus Control

Abstract

The micronutrient selenium is considered as tumor-protective, inter alia in its function as part of the selenium-dependent glutathione peroxidase (GPx), which exerts important antioxidative capacity within the cellular glutathione redox system. Over the last three decades, special interest has focused in this context on prospective epidemiological studies as well as on comparative determinations of selenium and the GPx in blood of cancer patients versus control. Little data has become available in relation to comparative determinations in tissue. Therefore, in the present study we determined selenium and the selenium-dependent GPx in blood and tissue of cancer patients versus control. Patients (n = 100) with a broad spectrum of cancer entities, such as ovarian, breast, stomach, and colorectal cancers, showed significantly diminished whole blood selenium compared to controls (n = 103; p < 0.001). At the same time, cancer tissue from ovary, breast, stomach, and colon/rectum contained higher levels of selenium than control tissue. The differences were significant for breast (p < 0.001) and colorectal cancer tissue (p < 0.001). Lower levels of selenium were found in cancer tissues of the endometrium. In patients with colorectal cancer, GPx activities in plasma (p < 0.05) and erythrocytes (p < 0.001) were, corresponding to the selenium levels significantly decreased, whereas activities in cancer tissue increased (p < 0.001). An increased antioxidative capacity in cancer tissue might be an indicator for anticancer drug-resistances. The results will be discussed while taking into account results from other authors, which were investigated on Medline. Further research on intratumoral characteristics in relation to selenium and the glutathione redox system may be of particular assistance to practical oncology.

Zusammenfassung

Das Spurenelement Selen gilt als tumorprotektiv, unter anderem in seiner Funktion als Bestandteil der selenabhängigen Glutathion-Peroxidase (GPx), die wichtige antioxidative Kapazitäten innerhalb des zellulären Glutathion-Redoxsystem wahrnimmt. Auf diesem Hintergrund fokussierte sich in den letzten drei Jahrzehnten spezielles Interesse auf prospektive epidemiologische Studien sowie auf vergleichende Bestimmungen von Selen und GPx im Blut von Tumorpatienten versus Kontrolle. Gering ist die Datenlage zu vergleichenden Untersuchungen im Gewebe. Deshalb bestimmten wir in dieser Studie Selen und die selenabhängige GPx im Blut und Gewebe von Tumorpatienten versus Kontrolle. Patienten (n = 100) mit einem breiten Spektrum von Tumorentitäten, darunter Ovarial-, Mamma-, Magen- und kolorektale Karzinome, zeigten signifikant geringere Vollblut-Selenspiegel im Vergleich zur Kontrolle (n = 103; p < 0,001). Gleichzeitig enthielten Tumorgewebe von Ovar, Mamma, Magen und Kolon/Rektum höhere Selengehalte als die Kontrolle. Die Unterschiede waren für Mammakarzinome (p < 0,001) und kolorektale Karzinome (p < 0,001) signifikant. Geringere Mengen an Selen als die Kontrolle wurde für karzinomatöses Gewebe des Endometriums gefunden. Korrespondierend zu den Selengehalten zeigten sich für Patienten mit kolorektalen Karzinomen signifikant erniedrigte GPx-Aktivitäten im Plasma (p < 0,05) und Erythrozyten (p < 0,001), dagegen erhöhte Aktivitäten im Tumorgewebe (p < 0,001). Erhöhte antioxidative Kapazitäten im Tumorgewebe stellen möglicherweise einen Indikator für Zytostatika-Resistenzen dar. Die Ergebnisse werden unter Berücksichtigung der durch eine Medline-Recherche erhobenen Studienergebnisse anderer Autoren diskutiert. Weiterführende Untersuchungen intratumoraler Charakteristika zu Selen und dem Glutathion-Redoxsystem könnten hilfreiche Erkenntnisse für die praktische Onkologie liefern.

Selenium - Glutathione peroxidase - Tissue - Blood - Anticancer drug-resistance

Selen - Glutathion-Peroxidase - Gewebe - Blut - Zytostatika-Resistenz

References

• 1 Raymann M P. the importance of selenium to human health.  Lancet. 2000;  356 233-241
• 2 Ursini F, Maiorino M, Brigelius-Flohé R, Aumann K D, Roveri A, Schomburg D, Flohé L. Diversity of glutathione peroxidases.  Methods Enzymology. 1995;  252 38-53
• 3 Combs G F, Gray W. Chemopreventive Agents: Selenium.  Pharmacol Ther. 1998;  79 179-192
• 4 Vincenti M, Rovesti S, Bergomi M, Vivoli G. The epidemiology of selenium and human cancer.  Tumori. 2000;  86 105-118
• 5 Bratakos M S, Vouterakos T P, Ioannou P V. Selenium status of cancer patients in Greece.  Sci Total Environ. 1990;  92 207-222
• 6 Pawlowic Z, Zachara B A, Trafikowska U, Maciag A, Marchaluk E, Nowicki A. Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer.  J Trace Elem Electrolytes Health Dis. 1991;  5 275-277
• 7 Lund-Pero M, Jeppson B, Pero R W. Reduced non specific steroidal esterase activity in human malignant tumor tissue from liver, colon and breast when compared to peritumoral and normal tissue levels.  Anticancer Res. 1994;  14 2747-2753
• 8 Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.  J Natl Cancer Inst. 1998;  90 455-460
• 9 Balasubramaniyan N, Subramanian S, Govindasamy S. Status of antioxidant systems in human carcinoma of uterine cervix.  Cancer Lett. 1994;  87 187-192
• 10 Oster O, Schmiedel G, Prellwitz W. The organ distribution of selenium in German adults.  Biol Trace Elem Res. 1988;  15 23-45
• 11 Hartfiel W, Bahners N. Selenium deficiency in the Federal Republic of Germany.  Biol Trace Elem Res. 1988;  15 1-12
• 12 Güntzler W A, Kremers H, Flohé L. An improved couplet test procedure for glutathione peroxidase in blood.  Z Klin Chem Klin Biochem. 1974;  10 444-448
• 13 Oster O, Schmiedel G, Prellwitz W. Correlations of blood selenium with hematological parameters in West German adults.  Biol Trace Elem Res. 1988;  15 47-52
• 14 Welz B, Melcher M, Neve J. Determination of selenium in human body fluids by hydride generation atomic absorption spectroscopy.  Anal Chim Acta. 1984;  165 131-139
• 15 Jendryczko A, Pardela M, Kozlowski A. Erythrocyte glutathione peroxidase in patients with colon cancer.  Neoplasma. 1993;  40 107-109
• 16 Djuric Z, Malviya V K, Deppe G, Malone J M, McGunagle D L, Heilbrun L K, Reading B A, Lawrence W D. Detoxifying enzymes in human ovarian tissues: comparison of normal and tumor tissues and effects of chemotherapy.  J Cancer Res Clin Oncol. 1990;  116 379-383
• 17 Abou Ghalia A H, Fuoad I M. Glutathione and its metabolizing enzymes in patients with different benign and malignant diseases.  Clin biochem. 2000;  33 657-662
• 18 Sharma K, Mittal D K, Kesarwani R C, Kamboj V P, Chowdhery. Diagnostic and prognostic significance of serum and tissue trace elements in breast malignancy.  Indian J Med Sci. 1994;  48 227-232
• 19 Rizk S L, Sky-Peck H H. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue.  Cancer Res. 1984;  144 5390-5394
• 20 Drake E N, Sky-Peck H H. Discriminant analysis of trace element distribution in normal and malignant human tissues.  Cancer Res. 1989;  49 4210-4215
• 21 Borella P, Bargellini A, Caselgrandi E, Piccinini L. Observations on the use of plasma, hair and tissue to evaluate trace element status in cancer.  J Trace Elem Med Biol. 1997;  11 162-165
• 22 Di Ilio C, Sacchetta P, Del Boccio G, La Rovere G, Federici G. Glutathione peroxidase, glutathione S-transferace and gluthatione reductase activities in normal and neoplastic human breast tissue.  Cancer Lett. 1985;  29 37-42
• 23 Howie A F, Forrester L M, Glancey M J, Schlager J J, Powis G, Beckett G J, Hayes J D, Wolf C R. Gluthatione S-transferase and glutathione peroxidase expression in normal and tumor human tissues.  Carcinogenesis. 1990;  11 451-458
• 24 Iscan M, Coban T, Bulbul D, Eke B C, Aygormez S, Berberoglu U. Xenobiotic metabolizing and antioxidant enzymes in normal and neoplastic human breast tissue.  Eur J Drug Metab Pharmacokinet. 1998;  23 497-500
• 25 Perquin M, Oster T, Maul A, Froment N, Untereiner M, Bagrel D. The glutathione-related detoxification pathway in the human breast: a highly coordinated system disrupted in the tumour tissues.  Cancer Lett. 2000;  158 7-16
• 26 Punnonen R, Kudo R, Punnonen K, Hietanen E, Kuoppala T, Kainulainen H, Sato K, Ahotupa M. Activities of antioxidant enzymes and lipid peroxidation in endometrial cancer.  Eur J Cancer. 1993;  29A 266-269
• 27 Ohwade M, Suzuki M, Sato I, Tsukamoto H, Watanabe K. Glutathione peroxidase activity in endometrium: effects of sex hormones and cancer.  Gynecol Oncol. 1996;  60 277-282
• 28 Burguera J L, Villasamil L M, Burguera M, Carrero P, Rondon C, Matousek A, Brunetto M R, Gallignani M. Gastric trissue selenium levels in healthy persons, cancer and non-cancer patients with different kinds of mucosal damage.  J Trace Elem Med Biol. 1995;  9 160-164
• 29 Wu C W, Wei Y Y, Chi C W, Lui W Y, P'eng F K, Chung C. Tissue potassium, selenium, and iron levels associated with gastric cancer progression.  Dig Dis Sci. 1996;  41 119-125
• 30 Baur G, Wendel A. The activity of the peroxide-metabolizing system in human colon carcinoma.  J Cancer Res Clin Oncol. 1980;  97 267-273
• 31 Öztürk H S, Karaayvaz M, Kacmaz M, Kavutcu M, Akgül H, Durak I. Activities of the enzymes participating in purine and free-readical metabolism in cancerous human colorectal tissues.  Cancer Biochem Biophys. 1998;  16 157-168
• 32 Siegers C-P, Bose-Younes H, Thies E, Hoppenkamps R, Younes M. Glutathione and GSH-dependent enzymes in the tumorous and non-tumorous mucosa of the human colon and rectum.  J Cancer Clin Oncol. 1984;  107 238-241
• 33 Mekhail-Ishak K, Hudson N, Tsao M S, Batist G. Implications for therapy of drug-metabolizing enzymes in human colon cancer.  Cancer Res. 1989;  49 4866-4869
• 34 Lewis A D, Hayes J D, Wolf R D. Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects.  Carcinogenesis. 1998;  9 1283-1287
• 35 Batist G, Tulpule A, Sinha B K, Katki A G, Myers C E, Xowan K H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells.  J Biol Chem. 1986;  261 544-549
• 36 Kartner N, Riordan J R, Ling V. Cell surface p-glycoprotein associated with multidrug resistance in mammalian cell lines.  Science. 1983;  221 1285-1287
• 37 Thorgeirsson S S, Huber B E, Sorrell S, Fojo A, Pastan I, Gottesman M M. Expression of the multi-drug resistant gene in hepatogenesis and regenerating rat liver.  Science. 1987;  236 1120-1122
• 38 Arrick B A, Nathan C F. Glutathione metabolism as a determinant of the therapeutic efficacy: a review.  Cancer Res. 1984;  33 4224-4232
• 39 Green J A, Vistica D T, Young R C. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.  Cancer Res. 1984;  44 5427-5431
• 40 Hamilton R C, Winkler M A, Louie K G, Batist G, Behrens B C, Tsuruo T, Grotzinger K R, McKoy W M, Young R C, Ozols R F. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.  Biochem Pharmacol. 1985;  34 2583-2586
• 41 Ohkawa K, Tsukada Y, Dohzono H, Koike K, Terashima Y. The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity.  Br J Cancer. 1988;  58 38-41
• 42 Baldew G S, van den Hamer C JA, Los G, Vermeulen N PE, Goeij J JM, McVie J G. Selenium-induced protection against cis-diamminedichloroplatinum (II) nephrotoxicity in mice and rats.  Cancer Res. 1989;  49 3020-3023
• 43 Roth T, Fiebig H-H. Cytotoxic profile of sodium selenite (selenase®) and sodium selenite in combination with clinically used chemotherapeutic agents in human tumor models in vitro.  Onkologie. 1999;  2 (2) 30-39